Q4 25 EPS
$1.50
BEAT +0.67%
Est. $1.49
Q4 25 Revenue
$11.46B
MISS 2.94%
Est. $11.81B
vs S&P Since Q4 25
-23.6%
TRAILING MARKET
ABT -19.1% vs S&P +4.6%
Full Year 2025 Results
FY 25 EPS
$5.15
MISS 0.42%
Est. $5.17
FY 25 Revenue
$44.33B
MISS 0.78%
Est. $44.67B
Market Reaction
Did ABT Beat Earnings? Q4 2025 Results
Abbott Laboratories delivered a mixed fourth-quarter 2025 report, edging past earnings expectations while falling short on revenue, as strength in Medical Devices was offset by weakness elsewhere in the portfolio. Adjusted diluted EPS came in at $1.5… Read more Abbott Laboratories delivered a mixed fourth-quarter 2025 report, edging past earnings expectations while falling short on revenue, as strength in Medical Devices was offset by weakness elsewhere in the portfolio. Adjusted diluted EPS came in at $1.50, a hair above the $1.49 consensus estimate for a 0.67% beat and 12% year-over-year growth, but revenue of $11.46 billion trailed the $11.81 billion consensus by 2.94%, even as sales grew 4.4% from a year earlier. The standout driver was the Medical Devices segment, which posted 12.3% reported growth fueled by continuous glucose monitor sales hitting $2.00 billion in the quarter, a 15% year-over-year gain that underscores growing demand for CGM technology alongside diabetes drug therapies. Nutrition remained a drag, falling 8.9% on deliberate pricing moves management hopes will restore volumes through 2026 product launches. Abbott also announced a $21 billion deal to acquire Exact Sciences, targeting cancer diagnostics. Looking ahead, the company guided for 6.5% to 7.5% organic sales growth in 2026 and adjusted EPS of $5.55 to $5.80, and extended its 54-year dividend growth streak with its 408th consecutive quarterly payout.
Key Takeaways
- • Double-digit growth in Electrophysiology, Heart Failure, Diabetes Care, and Rhythm Management
- • Continuous glucose monitor sales of $2.0 billion growing 15.0% reported
- • Established Pharmaceuticals growth led by double-digit gains in India, Latin America, and Middle East
- • Core Laboratory Diagnostics grew 5.3% reported
- • Margin expansion and double-digit EPS growth in full-year 2025
ABT YoY Financials
Q4 2025 vs Q4 2024, source: SEC Filings
ABT Revenue by Segment
With YoY comparisons, source: SEC Filings
ABT Revenue by Geography
With YoY comparisons, source: SEC Filings
“In 2025, we expanded margins and achieved double-digit earnings per share growth, our new product pipeline was highly productive, and we took important strategic steps to shape the company for the future. We're well positioned for accelerating growth in 2026.”
— Robert B. Ford, Q4 2025 Earnings Press Release
ABT Earnings Trends
ABT vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
ABT EPS Trend
Earnings per share: estimate vs actual
ABT Revenue Trend
Quarterly revenue: estimate vs actual
ABT Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | $1.15 | — | $11.16B | +1.51% |
| Q4 25 BEAT FY | $1.49 | $1.50 | +0.67% | $11.46B | -2.94% |
| FY Full Year | $5.17 | $5.15 | -0.42% | $44.33B | -0.78% |
| Q3 25 BEAT | $1.30 | $1.30 | +0.05% | $11.37B | -0.21% |
| Q2 25 BEAT | $1.25 | $1.26 | +0.80% | $11.14B | +1.08% |
| Q1 25 BEAT | $1.07 | $1.09 | +1.75% | $10.36B | -0.57% |